EGFR and non-small cell lung carcinoma: Important examples of oncogenic drivers of NSCLC are somatic EGFR mutations in exons 18-21, frequently identified (10-60% of lung adenocarcinomas9–11) among patients successfully treated with first-generation ATP-competing tyrosine kinase inhibitors (TKIs)12, and in-frame insertions of three or more base pairs in exon 20 (Ex20Ins), unresponsive to TKIs and accounting for 4-10% of all EGFR mutations in NSCLC13.